Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Tuberculosis

  Free Subscription


26.02.2018

3 Antimicrob Agents Chemother
7 Emerg Infect Dis
1 JAMA
2 Lancet Infect Dis
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Antimicrob Agents Chemother

  1. CHEN C, Gardete S, Jansen RS, Shetty A, et al
    Verapamil targets membrane energetics in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02107.
    PubMed     Text format     Abstract available

  2. HEMANTH KUMAR AK, Kumar A, Kannan T, Bhatia R, et al
    Pharmacokinetics of second-line anti-tuberculosis drugs in children with multidrug-resistant tuberculosis in India.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02410.
    PubMed     Text format     Abstract available

  3. WEINER M, Gelfond J, Johnson-Pais TL, Engle M, et al
    Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.01802.
    PubMed     Text format     Abstract available


    Emerg Infect Dis

  4. CHERNYAEVA E, Rotkevich M, Krasheninnikova K, Yurchenko A, et al
    Whole-Genome Analysis of Mycobacterium tuberculosis from Patients with Tuberculous Spondylitis, Russia.
    Emerg Infect Dis. 2018;24:579-583.
    PubMed     Text format     Abstract available

  5. RANDO-SEGURA A, Aznar ML, Moreno MM, Espasa M, et al
    Drug Resistance of Mycobacterium tuberculosis Complex in a Rural Setting, Angola.
    Emerg Infect Dis. 2018;24:569-572.
    PubMed     Text format     Abstract available

  6. ALTHOMSONS SP, Hill AN, Harrist AV, France AM, et al
    Statistical Method to Detect Tuberculosis Outbreaks among Endemic Clusters in a Low-Incidence Setting.
    Emerg Infect Dis. 2018;24:573-575.
    PubMed     Text format     Abstract available

  7. NAIK PR, Moonan PK, Nirgude AS, Shewade HD, et al
    Use of Verbal Autopsy to Determine Underlying Cause of Death during Treatment of Multidrug-Resistant Tuberculosis, India.
    Emerg Infect Dis. 2018;24:478-484.
    PubMed     Text format     Abstract available

  8. NGUYEN DT, Teeter LD, Graves J, Graviss EA, et al
    Characteristics Associated with Negative Interferon-gamma Release Assay Results in Culture-Confirmed Tuberculosis Patients, Texas, USA, 2013-2015.
    Emerg Infect Dis. 2018;24:534-540.
    PubMed     Text format     Abstract available

  9. BRENT AJ, Nyundo C, Langat J, Mulunda C, et al
    Prospective Observational Study of Incidence and Preventable Burden of Childhood Tuberculosis, Kenya.
    Emerg Infect Dis. 2018;24:514-523.
    PubMed     Text format    

  10. YEN YF, Pan SW, Su VY, Chuang PH, et al
    Influenza Vaccination and Incident Tuberculosis among Elderly Persons, Taiwan(1).
    Emerg Infect Dis. 2018;24:498-505.
    PubMed     Text format     Abstract available


    JAMA

  11. ABBASI J
    Urine Test for Tuberculosis in Development.
    JAMA. 2018;319:539.
    PubMed     Text format    


    Lancet Infect Dis

  12. FERLAZZO G, Mohr E, Laxmeshwar C, Hewison C, et al
    Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Lancet Infect Dis. 2018 Feb 13. pii: S1473-3099(18)30100.
    PubMed     Text format     Abstract available

  13. TADOLINI M, Tiberi S, Migliori GB
    Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.
    Lancet Infect Dis. 2018 Feb 13. pii: S1473-3099(18)30106.
    PubMed     Text format    


    PLoS One

  14. GAUTAM SS, Mac Aogain M, Cooley LA, Haug G, et al
    Molecular epidemiology of tuberculosis in Tasmania and genomic characterisation of its first known multi-drug resistant case.
    PLoS One. 2018;13:e0192351.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: